Abstract:Background and objective: Screening for bladder cancer (BCa) could reduce mortality via early detection of early-stage high-grade (Ta/T1 N0 M0 grade 2-3) disease. Noninvasive biomarkers could aid in screening, but current markers lack the specificity required. The urinary free glycosaminoglycan profile (GAGome) is a promising biomarker for early detection of BCa metabolism. Methods: In a prospective case-control development study, we included patients with BCa or no evidence of disease (NED) and measured the urinary GAGome. We then developed a score to predict the probability of BCa using GAGome features that correlated with BCa versus NED according to Bayesian regression. Next, in a retrospective, population-based, case-control study, we included adults from the Lifelines Cohort Study who were presumed healthy at baseline. All cases with BCa confirmed in the cancer registry by the 2-yr or 6-yr study visit were matched to randomly selected control subjects. We developed a reference logistic regression model using age and sex to predict BCa at 7 yr after baseline. We then added the GAGome score to the model and assessed model improvement using the likelihood ratio test. We dichotomized outputs for the reference model and saturated model (reference + GAGome score) into high-risk versus low-risk categories using a 99% specificity cutoff and estimated the sensitivity for association with BCa at 7 yr. Key findings and limitations: We prospectively included 51 individuals with BCa and 38 with NED and observed alterations in three GAGome features compatible with BCa. We developed a score that discriminated BCa with an area under the receiver operating characteristic curve of 0.77 (95% confidence interval [CI] 0.67-0.87). We retrospectively selected a cohort of 1088 presumed healthy adults (median age 48 yr, 56% females), of whom 48 had developed BCa by 7 yr after baseline (median time to diagnosis 1.4 yr). The GAGome score was an independent predictor of BCa at 7 yr when added to the reference model (p < 0.001). The sensitivity for BCa at 7 yr for high-risk subjects was 31% (95% CI 20-43%) using the saturated model and 17% (95% CI 4.7-29%) using the reference model at 99% specificity (95% CI 98-99%). Conclusions and clinical implications: The urinary free GAGome is specifically altered in BCa and can be used for noninvasive identification of adults at high risk of developing BCa, independent of age and sex. This information could be useful for the design of risk-stratified targeted screening programs for BCa. Patient summary: We tested whether measurement of a class of sugars called glycosaminoglycans (GAGs) in urine could be used for early detection of bladder cancer. Our results show that GAG levels in urine can distinguish people at high risk of developing bladder cancer within 7 years, even if they are healthy at the time of the urine sampling.

Structural Alterations and Its Significance of Sugar Chains in Urine Fibronectin from Bladder Cancer Patients

Chromosome aberration of urine exfoliated cells to diagnose bladder neoplasm by fluorescence in situ hybridization

Effectiveness of urine fibronectin as a non-invasive diagnostic biomarker in bladder cancer patients: a systematic review and meta-analysis

Urinary Cellular Fibronectin in Diagnosis and Postoperative Surveillance of Bladder Cancer

Structural alterations and significance of sugar chains of PSA in urine and blood from BPH and Pca patients

Primary Studies on the Changes of Structures of Sugar Chains and the Mechanisms of N-acetylglucosaminyl-transferase(GnT) in Cholangiocarcinoma Bile

Expression and Significance of Bladder Cancer Specific Nuclear Matrix Protein 4 and Cytokeratin 19 Fragment in Urine of Patients with Bladder Cancer

Expression of Fibronectin, Laminin and Collagen Ⅳ in Rat Bladder Cancer

Alteration in N-Acetylglucosaminyltransferase Activities and Glycan Structure in Tissue and Bile Glycoproteins from Extrahepatic Bile Duct Carcinoma

Value of Urinary Bladder Cancer Antigen, CYFRA21-1 and Hyaluronic Acid in the Diagnosis of Bladder Cancer

Diagnosis of urothelial carcinoma of bladder by test paper of urinary fibronectin

Urine Gamma-Synuclein As a Biomarker for the Diagnosis of Bladder Cancer

Aberrantly glycosylated integrin α3β1 is a unique urinary biomarker for the diagnosis of bladder cancer.

Novel Non-Invasive Diagnosis of Bladder Cancer in Urine Based on Multifunctional Nanoparticles

Study on the abnormal expression of carbohydrate antigen 19-9 in the urine samples of the patients with bladder cancer

Elevated level of serum glycoprotein bifucosylation and prognostic value in Chinese breast cancer

Urinary Free Glycosaminoglycans Identify Adults at High Risk of Developing Early-stage High-grade Bladder Cancer

Identification of novel protein biomarkers from the blood and urine for the early diagnosis of bladder cancer via proximity extension analysis

Fibronectin urothelial gene expression as a new reliable biomarker for early detection of local toxicity secondary to adjuvant intravesical therapy for non-muscle invasive bladder cancer

Changes in terminal sialyl residues linked to N-glycans in the tissue of bile duct carcinoma and bile glycoproteins

Data from Urinary Glycoprotein Biomarker Discovery for Bladder Cancer Detection Using LC/MS-MS and Label-Free Quantification